Bright Minds Biosciences Inc (DRUG) — Financial Flexibility Index

Latest as of March 2026: -2.48x

Bright Minds Biosciences Inc (DRUG) has a Financial Flexibility Index of -2.48x as of March 2026. Free cash flow of $-9.50 Million (operating CF $-9.50 Million minus capex $4.18) represents -2% of total liabilities ($3.83 Million). Check Bright Minds Biosciences Inc investment reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.

Financial Flexibility Index

-2.48x
Free Cash Flow / Total Liabilities

Free Cash Flow

$-9.50 Million
Operating CF − Capex

Total Liabilities

$3.83 Million
USD

Capital Expenditures

$4.18
USD

Bright Minds Biosciences Inc Financial Flexibility Index (2019–2025)

Historical Financial Flexibility Index trend for Bright Minds Biosciences Inc across 7 annual periods. For the full cash flow conversion analysis, see cash efficiency ratio of Bright Minds Biosciences Inc.

Annual Financial Flexibility Index for Bright Minds Biosciences Inc (2019–2025)

Year-by-year free cash flow to debt coverage for Bright Minds Biosciences Inc. Explore debt repayment capacity of Bright Minds Biosciences Inc to assess how comfortably operating cash covers total debt obligations.

Year Flexibility Index Free Cash Flow (USD) Operating CF Total Liabilities YoY Change
2025 -3.66x $-8.69 Million $-8.69 Million $2.38 Million ▼ -12.3%
2024 -3.26x $-1.85 Million $-1.85 Million $568.26K ▲ +87.0%
2023 -25.01x $-7.02 Million $-7.02 Million $280.86K ▼ -184.3%
2022 -8.80x $-13.59 Million $-13.59 Million $1.54 Million ▲ +23.2%
2021 -11.46x $-7.32 Million $-7.32 Million $638.57K ▼ -499.8%
2020 -1.91x $-288.39K $-288.39K $150.92K ▼ -67.0%
2019 -1.14x $-42.01K $-42.01K $36.71K
Financial Flexibility Index = (Operating CF − Capex) / Total Liabilities = Free Cash Flow / Total Liabilities